Bio Nano Consulting
(BNC), the specialist bio-nanotechnology product development consultancy,
has signed a collaborative agreement with a Top 5 pharma company to develop
new assay systems for their product discovery and development.
The agreement is the eighth major contract won by BNC in 2008, and follows
the completion in mid December of a second contract with Targanta Therapeutics
Corporation, in which BNC used world-leading cantilever-array assay system technology
to analyse the mechanism of action of Targanta's novel lipoglycopeptide antibiotic,
Commenting on the new contract, Dr David Sarphie, CEO of Bio Nano Consulting
said, "Nanotechnology is finding more and more applications in industry,
and BNC is developing a well-deserved reputation within the pharmaceutical,
biotech, medtech and healthcare industries for providing novel approaches in
research and development. With the unparalleled expertise of scientists at UCL's
London Centre for Nanotechnology, the Institute of Biomedical Engineering at
Imperial College and the National Physical Laboratory, BNC is ideally placed
to offer nanotechnology solutions in these sectors".